Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 17, 2018 - Issue 2
Submit an article Journal homepage
1,143
Views
16
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders

Maurizio PompiliDepartment of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, ItalyCorrespondence[email protected]
,
Claudio VerzuraPsychiatry Residency Training Program, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
,
Giada TroviniPsychiatry Residency Training Program, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
,
Andrea BuscajoniPsychiatry Residency Training Program, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
,
Giulia FalconePsychiatry Residency Training Program, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
,
Stefano NaimPsychiatry Residency Training Program, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
,
Adele NardellaPsychiatry Residency Training Program, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
,
Serena SoricePsychiatry Residency Training Program, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
,
Ross J BaldessariniDepartment of Psychiatry, Harvard Medical School; International Consortium for Bipolar and Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Boston, MA, USA
&
Paolo GirardiDepartment of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy
 show all
Pages 197-205 | Received 28 Jun 2017, Accepted 11 Sep 2017, Published online: 26 Sep 2017

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Gayatri Saraf, Jairo Vinícius Pinto & Lakshmi N. Yatham. (2019) Efficacy and safety of cariprazine in the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy 20:17, pages 2063-2072.
Read now
Elie Cheniaux & Antonio E. Nardi. (2019) Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder. Expert Opinion on Drug Safety 18:10, pages 893-913.
Read now

Articles from other publishers (14)

Samuel Pàmpols-Pérez, Arnau Gisbert-Solà, Belen Resa-Pérez, Andrea Jiménez-Mayoral, Irene Forcada-Pach & Vicent Llorca-Bofi. (2023) Neuroleptic Malignant Syndrome Associated With Lurasidone. Journal of Clinical Psychopharmacology 43:6, pages 548-549.
Crossref
Masaki Kato, Takahiro Masuda, Fumiya Sano & Tadafumi Kato. (2023) The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials. Journal of Affective Disorders 337, pages 150-158.
Crossref
Jared W. Castle, Danielle M. Butzbach, G. Stewart Walker, Claire E. Lenehan, Frank Reith, Samuel P. Costello & K. Paul Kirkbride. (2023) Microbial degradation products of lurasidone and their significance in postmortem toxicology. Drug Testing and Analysis 15:5, pages 551-565.
Crossref
María Elena Gamboa-Arancibia, Nelson Caro, Alexander Gamboa, Javier Octavio Morales, Jorge Enrique González Casanova, Diana Marcela Rojas Gómez & Sebastián Miranda-Rojas. (2023) Improving Lurasidone Hydrochloride’s Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin. Pharmaceutics 15:1, pages 232.
Crossref
Yu-Ning Her, Hsin-An Chang, Fan-Jung Wan & Nian-Sheng Tzeng. (2023) Lurasidone treatment for delusional infestation in a patient with dementia. Journal of Medical Sciences 43:2, pages 79.
Crossref
Siu Wa Tang, Wayne H. Tang & Brian E. Leonard. (2021) Treatment-induced mood switching in affective disorders. Acta Neuropsychiatrica 34:2, pages 55-68.
Crossref
André Do, Kamyar Keramatian, Ayal Schaffer & Lakshmi Yatham. (2021) Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials. Frontiers in Psychiatry 12.
Crossref
Hui Wang, Ling Xiao, Hui-Ling Wang & Gao-Hua Wang. (2020) Efficacy and safety of lurasidone versus placebo as adjunctive to mood stabilizers in bipolar I depression: A meta-analysis. Journal of Affective Disorders 264, pages 227-233.
Crossref
Okada, Fukuyama, Okubo, Shiroyama & Ueda. (2019) Lurasidone Sub-Chronically Activates Serotonergic Transmission via Desensitization of 5-HT1A and 5-HT7 Receptors in Dorsal Raphe Nucleus. Pharmaceuticals 12:4, pages 149.
Crossref
Motohiro Okada, Kouji Fukuyama & Yuto Ueda. (2019) Lurasidone inhibits NMDA receptor antagonist‐induced functional abnormality of thalamocortical glutamatergic transmission via 5‐HT 7 receptor blockade . British Journal of Pharmacology 176:20, pages 4002-4018.
Crossref
. (2019) Evidence-Based Principles for Bipolar Disorder Treatment. FOCUS 17:3, pages 272-274.
Crossref
VivekC Kirpekar, AbhijeetD Faye, SudhirH Bhave, Rahul Tadke & Sushil Gawande. (2019) Lurasidone-induced anemia: Is there a need for hematological monitoring?. Indian Journal of Pharmacology 51:4, pages 276.
Crossref
Piotr Stępnicki, Magda Kondej & Agnieszka A. Kaczor. (2018) Current Concepts and Treatments of Schizophrenia. Molecules 23:8, pages 2087.
Crossref
Wei Zheng, Dong-Bin Cai, Xin-Hu Yang, Lu Li, Qing-E. Zhang, Chee H. Ng, Gabor S. Ungvari, Xian-Bin Li, Yu-Ping Ning & Yu-Tao Xiang. (2018) Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychiatric Research 103, pages 244-251.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.